Meeting
2020 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
Authors
Michele Ly
Memorial Sloan Kettering Cancer Center, New York, NY
Michele Ly , Daniela Molena , Smita Sihag , Abraham Jing-Ching Wu , Pari M. Shah , Ping Gu , Ryan Sugarman , Steven Brad Maron , Sree Bhavani Chalasani , Marina Shcherba , Randy Yeh , Laura H. Tang , Carly Alterman , Paige Collins , Kendall Cowie , Yelena Yuriy Janjigian , David H. Ilson , Geoffrey Yuyat Ku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02962063
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 394)
Abstract #
394
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.
First Author: Darren Cowzer
Poster
2021 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.
First Author: Patricio Eduardo Yanez